Boston Scientific (NYSE:BSX) Trading Down 5.2% – Here’s What Happened
by Scott Moore · The Cerbat GemBoston Scientific Corporation (NYSE:BSX – Get Free Report) dropped 5.2% during mid-day trading on Monday . The company traded as low as $61.16 and last traded at $60.8740. Approximately 10,645,930 shares traded hands during trading, a decline of 31% from the average daily volume of 15,535,610 shares. The stock had previously closed at $64.23.
Key Boston Scientific News
Here are the key news stories impacting Boston Scientific this week:
- Positive Sentiment: Piper Sandler reaffirmed an Overweight rating on BSX, a sign that at least some sell-side analysts remain constructive after the WATCHMAN/CHAMPION-AF readout. Here’s What Piper Sandler Thinks About Boston Scientific Corp (BSX) Now
- Positive Sentiment: Multiple firms have issued buy/overweight ratings (Needham, Truist, BTIG, RBC), and analysts’ median 6‑month targets remain well above the current price—support for longer‑term upside from Wall Street coverage.
- Neutral Sentiment: Boston Scientific reported positive CHAMPION‑AF/WATCHMAN FLX trial endpoints and plans to use the data in regulatory submissions — a potential upside over time but markets are debating how quickly this converts into procedure growth and reimbursement gains ahead of near‑term results. Boston Scientific (BSX) slips 3.3% as investors stay cautious ahead of upcoming results and after recent trial and legal headlines
- Neutral Sentiment: The company faces an immediate market catalyst: quarterly results scheduled for April 22. Pre‑earnings de‑risking often increases volatility and can pressure the stock short‑term.
- Neutral Sentiment: Longer‑term market drivers: industry reports point to multi‑year growth in drug‑eluting stents and other medtech segments, which supports BSX’s market opportunity though this is a gradual tailwind. Drug-Eluting Stents – Global Market Trends, Developments and Investment Opportunities 2026-2034
- Negative Sentiment: Heightened legal/headline risk: multiple firms have filed or are soliciting lead‑plaintiff candidates in a securities class action covering July 23, 2025–Feb 3, 2026, with a May 4 deadline to seek lead‑plaintiff status. That wave of notices and reminders increases headline volatility and may prompt selling. Robbins LLP Encourages BSX Stockholders to Contact the Firm for Information About the Class Action Against Boston Scientific Deadline Alert: Boston Scientific Corporation (BSX) Shareholders Urged To Contact Glancy Prongay Wolke & Rotter LLP
- Negative Sentiment: Insider and institutional activity shows net selling: recent disclosures and institutional quarter‑end trims (including large reductions at some asset managers) and multiple insider sales have been flagged by data providers — a signaling factor that can weigh on sentiment. Boston Scientific (BSX) slips 3.3% as investors stay cautious ahead of upcoming results and after recent trial and legal headlines
Wall Street Analyst Weigh In
BSX has been the topic of a number of recent analyst reports. TD Cowen dropped their price target on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. UBS Group dropped their target price on Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research report on Tuesday, March 17th. Morgan Stanley dropped their target price on Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Evercore dropped their target price on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Finally, Barclays dropped their target price on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $102.82.
Check Out Our Latest Report on Boston Scientific
Boston Scientific Stock Down 5.0%
The company has a market capitalization of $90.66 billion, a PE ratio of 31.45, a P/E/G ratio of 0.99 and a beta of 0.78. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The company has a 50-day moving average of $69.60 and a two-hundred day moving average of $86.83.
Boston Scientific (NYSE:BSX – Get Free Report) last released its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter in the previous year, the company earned $0.70 EPS. Boston Scientific’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.
Insider Activity at Boston Scientific
In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.34% of the company’s stock.
Institutional Trading of Boston Scientific
Several hedge funds have recently bought and sold shares of the stock. Vanderbilt University lifted its stake in Boston Scientific by 20.9% in the 1st quarter. Vanderbilt University now owns 39,470 shares of the medical equipment provider’s stock worth $2,477,000 after purchasing an additional 6,836 shares in the last quarter. BTC Capital Management Inc. raised its stake in Boston Scientific by 57.6% during the first quarter. BTC Capital Management Inc. now owns 84,238 shares of the medical equipment provider’s stock valued at $5,285,000 after purchasing an additional 30,778 shares in the last quarter. Fifth Third Wealth Advisors LLC raised its stake in Boston Scientific by 5.4% during the first quarter. Fifth Third Wealth Advisors LLC now owns 53,099 shares of the medical equipment provider’s stock valued at $3,332,000 after purchasing an additional 2,712 shares in the last quarter. Brown Lisle Cummings Inc. raised its stake in Boston Scientific by 1.8% during the first quarter. Brown Lisle Cummings Inc. now owns 75,763 shares of the medical equipment provider’s stock valued at $4,754,000 after purchasing an additional 1,320 shares in the last quarter. Finally, OP Asset Management Ltd purchased a new stake in Boston Scientific during the first quarter valued at $9,419,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.
About Boston Scientific
Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.
Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.